Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm
Key Points
The disposition of 6,289 shares at $61.20 per share represented a transaction value of about $384,900.
The transaction involved shares equal to 0.87% of the total equity stake held before the filing, resulting in a minor reduction of the overall position.
The shares were withheld by the issuer to satisfy tax obligations related to the vesting of restricted stock units.
- 10 stocks we like better than Vaxcyte ›
Grant Pickering, the chief executive officer of Vaxcyte, Inc. (NASDAQ:PCVX), disposed of 6,289 shares of common stock in a non-discretionary transaction, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold | 6,289 |
| Transaction value | ~$384,900 |
| Post-transaction shares (directly held) | ~447,000 |
| Post-transaction shares (indirectly held) | ~266,400 |
| Post-transaction value | $43.93 million |
Transaction value based on SEC Form 4 weighted average sale price ($61.20); post-transaction value based on the September 2 market close ($61.58).
Key questions
- Was the disposal a discretionary market sale?
The transaction was non-discretionary, as the shares were surrendered to the issuer solely to cover tax withholding obligations realized upon the vesting of restricted stock units. - How has the stock performed leading up to this filing?
Vaxcyte common stock has delivered a 95% total return over the 12-month period ending on the August 31 transaction date. - What is the breakdown of the CEO's indirect equity holdings?
Pickering's indirect position of 266,430 shares is divided equally between two separate trusts, with 133,215 shares held for his son and 133,215 shares held for his daughter. - What is the status of Vaxcyte's clinical pipeline?
The biotechnology company is currently focused on the clinical development of VAX-24, an experimental 24-valent pneumococcal conjugate vaccine in trials designed to address invasive pneumococcal disease and pneumonia.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-09-01) | $60.81 |
| Market Capitalization | $9.0 billion |
| Net Income (TTM) | -$1.1 billion |
| One Year Share Price Change | +95% |
Company Snapshot
- Vaxcyte is a clinical-stage biotechnology company focused on developing innovative protein-based vaccines to prevent and manage bacterial infectious diseases, with its lead candidate VAX-24, a 24-valent pneumococcal conjugate vaccine currently in clinical trials.
- The company operates a development-stage business model centered on advancing proprietary vaccine candidates through clinical trials with the objective of eventual commercialization and licensing partnerships with established pharmaceutical entities.
- Vaxcyte's primary target markets include healthcare systems, public health agencies, and pharmaceutical partners seeking next-generation vaccines to address unmet medical needs in infectious disease prevention, particularly in immunocompromised and elderly populations.
Vaxcyte, Inc. is a clinical-stage biotechnology enterprise headquartered in San Carlos with 507 employees, focused on developing next-generation protein-based vaccines addressing significant gaps in infectious disease prevention. The company's strategic approach leverages advanced conjugate vaccine technology to create multivalent formulations with enhanced immunogenicity and broader pathogen coverage than existing therapeutic options. With a market capitalization of $9.0 billion and a one-year share price appreciation of 95.12%, Vaxcyte represents investor confidence in its clinical pipeline and the substantial market opportunity within the global vaccine sector.
What this transaction means for investors
Pickering surrendered 6,289 shares to Vaxcyte for taxes when restricted stock vested, a rounding error against the 266,430 shares sitting in trusts for his two children. More importantly, he co-founded the company and runs it, and what he's running now relies on data set for release in the near future.
Vaxcyte expects topline data in the fourth quarter from OPUS-1, the pivotal Phase 3 trial testing VAX-31, its 31-strain pneumococcal vaccine, head to head against Pfizer's Prevnar 20 and Merck's Capvaxive in about 4,000 adults aged 50 and up. Two supporting trials read out in the first half of 2027, and only then does a filing for approval follow. The company remains "on track" for that release, Pickering said in an August 5 release.
Meanwhile, Vaxcyte burned $284.3 million in the June quarter alone, with R&D up 38% year over year to $267.9 million as manufacturing scales for a launch that hasn't been approved. The $2.5 billion in cash buys time, but a miss in OPUS-1 spends it on a vaccine that never sells. Right now, the company certainly has momentum so investors should stay focused on whether trial data helps that hold up.
Should you buy stock in Vaxcyte right now?
Before you buy stock in Vaxcyte, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vaxcyte wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $421,997!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,413,876!*
Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of September 8, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
